{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:53:48Z","timestamp":1776401628325,"version":"3.51.2"},"reference-count":51,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Foundation for medical-biological Research","award":["20C215"],"award-info":[{"award-number":["20C215"]}]},{"name":"Department of Dermatology Inselspital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients with HS, including on their cardiovascular risk and quality of life. Methods: A literature search was conducted on Embase and PubMed, yielding 300 papers, of which 10 were used for this review. Results: HS patients using GLP-1 agonists showed improved clinical course with less pain and suppuration. Further, patients\u2019 quality of life and mental health improved and their cardiovascular risk was reduced. Inflammatory parameters showed no significant changes. Patients receiving a higher drug dose of GLP-1 agonists were more likely to show clinical improvement. A reduction in weight or BMI did not correlate with improvements in Hurley stage, pain or depression. Hence, HS patients could be treated with GLP-1 agonists. Conclusions: Therefore, whether patients\u2019 improvement is due to weight loss, or other mechanisms, i.e., GLP-1 agonists\u2019 anti-inflammatory properties, remains to be determined in further studies.<\/jats:p>","DOI":"10.3390\/jcm15082909","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:49:02Z","timestamp":1776070142000},"page":"2909","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5517-3904","authenticated-orcid":false,"given":"Annik","family":"Caliezi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aref","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland"},{"name":"Institute of Pharmacology, University of Bern, Rosenb\u00fchlgasse 27, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0799","authenticated-orcid":false,"given":"Ronald","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Morteza","family":"Seyed Jafari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Inselspital, Anna-Seiler-Allee 33, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis Suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1111\/jdv.20358","article-title":"Mental Health in Hidradenitis Suppurativa: A Complex Matter","volume":"39","author":"Bouwman","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Caliezi, A., Rabufetti, A., Hunger, R., Wolf, R., and Seyed Jafari, S.M. (2025). Impact of Hidradenitis Suppurativa on Sexual Quality of Life. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030910"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chernyshov, P.V., Finlay, A.Y., Tomas-Aragones, L., Poot, F., Sampogna, F., Marron, S.E., Zemskov, S.V., Abeni, D., Tzellos, T., and Szepietowski, J.C. (2021). Quality of Life in Hidradenitis Suppurativa: An Update. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18116131"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vossen, A.R.J.V., van der Zee, H.H., and Prens, E.P. (2018). Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways into a Cohesive Pathogenic Model. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02965"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/bjd\/ljac107","article-title":"Adipokines as an Important Link between Hidradenitis Suppurativa and Obesity: A Narrative Review","volume":"188","author":"Krajewski","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jid.2018.12.031","article-title":"Dermal White Adipose Tissue: A Newly Recognized Layer of Skin Innate Defense","volume":"139","author":"Chen","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.clindermatol.2025.05.009","article-title":"The Comorbidities of Hidradenitis Suppurativa","volume":"43","author":"Cesur","year":"2025","journal-title":"Clin. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","article-title":"Cardiovascular Disease Risk Factors in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Observational Studies","volume":"173","author":"Tzellos","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Hidradenitis Suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_12","first-page":"488","article-title":"Real-World Evidence\u2014Biosimilars Can Successfully Substitute Biologics in Psoriasis and Hidradenitis Suppurativa","volume":"42","author":"Wegner","year":"2025","journal-title":"Adv. Dermatol. Allergol. Dermatol. Alergol."},{"key":"ref_13","first-page":"830","article-title":"Color Doppler as a Tool for Correlating Vascularization and Pain in Hidradenitis Suppurativa Lesions","volume":"25","author":"Nazzaro","year":"2019","journal-title":"Skin Res. Technol."},{"key":"ref_14","first-page":"5887","article-title":"Non-Contrast-Enhanced 3-Tesla Magnetic Resonance Imaging Using Surface-Coil and Sonography for Assessment of Hidradenitis Suppurativa Lesions","volume":"100","author":"Lak","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Molinelli, E., De Simoni, E., Candelora, M., Sapigni, C., Brisigotti, V., Rizzetto, G., Offidani, A., and Simonetti, O. (2023). Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues. Antibiotics, 12.","DOI":"10.3390\/antibiotics12060978"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.20399","article-title":"Biologic Survival in Hidradenitis Suppurativa: Much Done, More to Do","volume":"185","author":"Hambly","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-025-67701-9","article-title":"Comprehensive Evaluation of GLP-1 Receptor Agonists: An Umbrella Review of Clinical Outcomes across Multiple Diseases","volume":"17","author":"Kong","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity\u2014A Phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","article-title":"The Treatment of Hidradenitis Suppurativa with the Glucagon-like Peptide-1 Agonist Liraglutide","volume":"177","author":"Jennings","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdin.2025.07.003","article-title":"Decreased Incidence of Hidradenitis Suppurativa and Psoriasis in Diabetic Patients Treated with GLP-1 Receptor Agonists: A Retrospective Cohort Study","volume":"22","author":"Ching","year":"2025","journal-title":"JAAD Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/jdv.20874","article-title":"GLP-1RAs and Cardiovascular Risk Reduction in Hidradenitis Suppurativa: A Real-World Cohort Study","volume":"40","author":"Chou","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa","volume":"161","author":"Gouvrion","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdin.2025.05.004","article-title":"Patient-Reported Outcomes of Glucagon-like Peptide-1 Agonists on Hidradenitis Suppurativa Severity","volume":"21","author":"Gupta","year":"2025","journal-title":"JAAD Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaad.2024.11.039","article-title":"Semaglutide Use for Decreasing Hidradenitis Suppurativa Resource Utilization: A Retrospective Cohort Study Utilizing TriNetX","volume":"92","author":"Hill","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ijd.17910","article-title":"A-MACE-Ing: A Real-World Analysis of Semaglutide\u2019s Impact on Major Adverse Cardiovascular Events (MACE) in Patients with Hidradenitis Suppurativa","volume":"65","author":"Islam","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for Weight Loss in People with Obesity as an Adjunctive Treatment for Hidradenitis Suppurativa: Its Impact on Disease Control and Quality of Life","volume":"191","author":"Lyons","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the Treatment of Obesity among Patients with Hidradenitis Suppurativa","volume":"162","author":"Nicolau","year":"2024","journal-title":"Med. Cl\u00ednica"},{"key":"ref_28","first-page":"e662","article-title":"Impact of Semaglutide Use in Obese and Diabetic Patients with Hidradenitis Suppurativa","volume":"39","author":"Alora","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/12034754251320045","article-title":"GLP-1 Agonists in Patients with Hidradenitis Suppurativa: A Case Series","volume":"29","author":"Rames","year":"2025","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-Inflammatory Role of Glucagon-like Peptide 1 Receptor Agonists and Its Clinical Implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20101","DOI":"10.1038\/s41598-024-69818-1","article-title":"Hyperhomocysteinemia and Its Effect on Ageing and Language Functions\u2014HEAL Study","volume":"14","author":"Sandhya","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/PTT.S485061","article-title":"Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis Targets Ther."},{"key":"ref_34","first-page":"34","article-title":"The Use of GLP-1 Agonists in the Management of Cutaneous Disease","volume":"17","author":"Lal","year":"2024","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.3390\/cimb45050280","article-title":"Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management\u2014A Systematic Review","volume":"45","author":"Diaz","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory Actions of Glucagon-like Peptide-1\u2013Based Therapies beyond Metabolic Benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Z\u0142otowska, A., and Szepietowski, J.C. (2024). The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216292"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 Receptor Agonist Impairs Keratinocytes Inflammatory Signals by Activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Persson, C., Eaton, A., and Mayrovitz, H.N. (2025). A Closer Look at the Dermatological Profile of GLP-1 Agonists. Diseases, 13.","DOI":"10.3390\/diseases13050127"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., and Giuliani, F. (2019). The Role of Inflammation in Depression and Fatigue. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01696"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111580","DOI":"10.1016\/j.mehy.2025.111580","article-title":"The \u201cConflict Avoidance Theory of Inflammation-Induced Anxiety\u201d (CATIA): A Psychoneuroimmunologic Hypothesis","volume":"196","author":"Nelles","year":"2025","journal-title":"Med. Hypotheses"},{"key":"ref_42","first-page":"S10","article-title":"Hidradenitis Suppurativa: Beyond Skin Concerns to Focus on Cardiovascular Considerations","volume":"18","author":"Flynn","year":"2025","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamadermatol.2025.2989","article-title":"Cardiometabolic Risk Factors and Cardiovascular Risk in Hidradenitis Suppurativa","volume":"161","author":"Dons","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jakubowski, H., and Witucki, \u0141. (2025). Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020746"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e214214","DOI":"10.1212\/WNL.0000000000214214","article-title":"Anti-Inflammatory Therapies for Atherosclerotic Stroke Prevention","volume":"105","author":"Georgakis","year":"2025","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2018.05.010","article-title":"Critical Roles of Inflammation in Atherosclerosis","volume":"73","author":"Moriya","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","first-page":"53","article-title":"Clinical Impact of Liraglutide as a Treatment of Obesity","volume":"13","author":"Alruwaili","year":"2021","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1111\/jdv.20861","article-title":"Large Language Models in Evaluating Hidradenitis Suppurativa from Clinical Images","volume":"39","author":"Boostani","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ijd.17729","article-title":"Diagnostic Performance of GPT-4o and Gemini Flash 2.0 in Acne and Rosacea","volume":"64","author":"Boostani","year":"2025","journal-title":"Int. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2909\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:12:56Z","timestamp":1776399176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15082909"],"URL":"https:\/\/doi.org\/10.3390\/jcm15082909","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]}}}